Intra-cellular Therapies, Inc. v. Zydus Cadila
Infringement action filed 29 Aug 2024 in the United States District Court for the District of New Jersey and closed 10 Apr 2026, with 2 patents asserted. Recorded basis of termination: case consolidated.
Case record
- Patents involved
- US12070459B2US11980617B2
- Case no.
- 3:24-cv-08856
- Verdict cause
- Infringement action
- Court
- D.N.J.
- Court level
- District Court
- Case region
- New Jersey
- Chief judge
- None recorded
- Trial level
- First instance
- Filed – Closed
- 29 Aug 2024 – 10 Apr 2026
- Duration
- 589 days
- Basis of termination
- Case Consolidated
- Products & marks
- CAPLYTA® (lumateperone) capsules, 10.5 mg, 21 mg, and 42 mg
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
- Legal status
- Active
- Granted
- 27 Aug 2024
- Earliest priority
- 31 Aug 2018
- Est. expiry
- 30 Aug 2039
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- LI, PENG · DAVIS, ROBERT
- Classification
- A61K31/4985A61K9/00A61K9/16A61K9/48
- Prosecution counsel
- HOXIE & ASSOCIATES LLC
- Examiner
- STEVENS, MARK V
Methods of treating acute depression and/or acute anxiety
The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.
- Legal status
- Active
- Granted
- 14 May 2024
- Earliest priority
- 14 Dec 2018
- Est. expiry
- 27 Oct 2039
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- SNYDER, GRETCHEN · DAVIS, ROBERT · WENNOGLE, LAWRENCE P.
- Classification
- A61K31/4985A61K9/00A61K31/13A61K31/135A61K31/137A61K31/138A61K31/155A61K31/165A61K31/197A61K31/343A61K31/36A61K31/38A61K31/381A61K31/42A61K31/485A61K31/55A61K31/5513A61K38/07A61P25/24
- Prosecution counsel
- HOXIE & ASSOCIATES LLC
- Examiner
- ANDERSON, JAMES D.
Parties of record
Intra-cellular Therapies, Inc.
- Core tech
- A61K31/4985A61K9/00A61K9/16A61K9/48
- Counsel
- Katelyn O’Reilly · Lauren Ruth Malakoff · Liza M. Walsh
- Firm
- Walsh Pizzi O’Reilly Falanga LLP
Zydus Cadila
- Core tech
- Not recorded
- Counsel
- Not recorded
- Firm
- Not recorded
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Katelyn O’Reilly | Intra-cellular Therapies, Inc. | Plaintiff |
| Lauren Ruth Malakoff | Intra-cellular Therapies, Inc. | Plaintiff |
| Liza M. Walsh | Intra-cellular Therapies, Inc. | Plaintiff |
Basis of termination
From the record · verbatim“ORDERED that Civil Action Nos. 3:24-cv-04264; 3:24-cv-08845; 3:24-cv-08848; 3:24-cv-08850; 3:24-cv-08852; 3:24-cv-08854; 3:24-cv-08855; and 3:24-cv-08856 (the “Consolidated Actions”) are consolidated for all pretrial purposes;”
Case 3:24-cv-08856 · D.N.J. · closed 10 April 2026
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 3:24-cv-08856?
3:24-cv-08856 is a patent infringement action brought by Intra-cellular Therapies, Inc. against Zydus Cadila, filed on 29 Aug 2024 in the United States District Court for the District of New Jersey. The case closed on 10 April 2026.
Which patents were asserted in 3:24-cv-08856?
US12070459B2 (“Pharmaceutical capsule compositions comprising lumateperone mono-tosylate”), assigned to INTRA-CELLULAR THERAPIES, INC., currently active; US11980617B2 (“Methods of treating acute depression and/or acute anxiety”), assigned to INTRA-CELLULAR THERAPIES, INC., currently active. The record also lists CAPLYTA® (lumateperone) capsules, 10.5 mg, 21 mg, and 42 mg.
How was case 3:24-cv-08856 terminated?
The recorded basis of termination is case consolidated. The termination text reads: “ORDERED that Civil Action Nos. 3:24-cv-04264; 3:24-cv-08845; 3:24-cv-08848; 3:24-cv-08850; 3:24-cv-08852; 3:24-cv-08854; 3:24-cv-08855; and 3:24-cv-08856 (the “Consolidated Actions”) are consolidated for all pretrial purposes;”
How long did case 3:24-cv-08856 take?
589 calendar days, from filing on 29 Aug 2024 to closure on 10 April 2026.
Who were the attorneys and the judge in 3:24-cv-08856?
Katelyn O’Reilly, Lauren Ruth Malakoff and Liza M. Walsh are recorded as counsel for plaintiff Intra-cellular Therapies.
Disclaimer. This page reproduces publicly available court docket data for case 3:24-cv-08856 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.